Lab-Grown tumors used to test supercharged immune cells against breast cancer
NCT ID NCT05007379
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study collects tumor and blood samples from 100 breast cancer patients to grow mini-tumors (organoids) in the lab. Researchers will then test whether specially engineered immune cells called CAR-macrophages can destroy these mini-tumors. The goal is to see if this new cell therapy could be a future treatment for different types of breast cancer.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- CAR-macrophages
- What this could lead to
- If the CAR-macrophages show strong activity against the organoids, this could point toward a new cell-based treatment for breast cancer.
- What could go wrong
- This is a very early lab study using tumor samples, not a treatment trial in patients. The approach may not work in real bodies or may have unexpected side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Nov 2021
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
This is a cohort study conducted in breast cancer patients requiring a surgery or a tumor biopsy as part of their care.
- Ages
-
18 to 100 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Male or female aged 18 years or more * Histologically confirmed breast cancer at any stage * Requiring surgery or tumor biopsy as standard of care * Any or no systemic treatment * Signed informaed consent * Health insurance coverage Exclusion Criteria: * Opposed to biospecimen collection
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Breast cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Oscar Lambret Center
RECRUITINGLille, 59000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a faster radiation course match the standard one after breast reconstruction?
- Can High-Risk breast cancer patients skip an extra radiation boost?
- Radioactive probe lights up CD73 on breast tumors in PET scans
- Can time with horses help cancer patients feel better?
- Can an oral drug replace injections for advanced breast cancer?
- Can a common steroid shield breast cancer patients from a dangerous drug side effect?